BOSTON, Oct. 21 - As traditional robotics approaches the limits of its usefulness in drug discovery, biotech and pharma companies, beset by shrunken pipelines and pressed for time, have set their sites on a new breed of lab automation.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.